Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial
- 3 November 2010
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 126 (1), 221-226
- https://doi.org/10.1007/s10549-010-1235-y
Abstract
Endocrine therapy for breast cancer may affect cognition. The purpose of this study was to examine whether cognitive function improves after cessation of adjuvant endocrine therapy. Change in cognitive function was assessed in 100 postmenopausal breast cancer patients in the BIG 1-98 trial, who were randomized to receive 5 years of adjuvant tamoxifen or letrozole alone or in sequence. Cognitive function was evaluated by computerized tests during the fifth year of trial treatment (Y5) and 1 year after treatment completion (Y6). Cognitive test scores were standardized according to age-specific norms and the change assessed using the Wilcoxon signed-rank test. There was significant improvement in the composite cognitive function score from Y5 to Y6 (median of change = 0.22, effect size = 0.53, P < 0.0001). This improvement was consistent in women taking either tamoxifen or letrozole at Y5 (P = 0.0006 and P = 0.0002, respectively). For postmenopausal patients who received either adjuvant letrozole or tamoxifen alone or in sequence, cognitive function improved after cessation of treatment.Keywords
This publication has 17 references indexed in Scilit:
- The FDA-NIMH-MATRICS Guidelines for Clinical Trial Design of Cognitive-Enhancing Drugs: What Do We Know 5 Years Later?Schizophrenia Bulletin, 2010
- The acute effects of d-amphetamine and methamphetamine on attention and psychomotor performancePsychopharmacology, 2006
- Assessing cognitive function in cancer patientsSupportive Care in Cancer, 2006
- A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast CancerNew England Journal of Medicine, 2005
- Cognitive impairment associated with adjuvant therapy in breast cancerPsycho‐Oncology, 2005
- A method for determining the magnitude of change across different cognitive functions in clinical trials: the effects of acute administration of two different doses alprazolamHuman Psychopharmacology: Clinical and Experimental, 2005
- Effects of d-amphetamine in human models of information processing and inhibitory controlDrug and Alcohol Dependence, 2004
- Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot studyPsycho‐Oncology, 2003
- Computerised cognitive assessment of athletes with sports related head injuryBritish Journal of Sports Medicine, 2001
- Relationship of Age and Menopausal Status to Estrogen Receptor Content in Primary Carcinoma of the BreastAnnals of Surgery, 1983